共 351 条
[1]
Hanahan D(2011)Hallmarks of cancer: the next generation Cell 144 646-674
[2]
Weinberg Robert A(2014)New insights into cancer immunoediting and its three component phases–elimination, equilibrium and escape Curr Opin Immunol 27 16-25
[3]
Mittal D(2006)Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science (New York, NY) 313 1960-1964
[4]
Gubin MM(2014)Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab J Clin Oncol 32 1020-1030
[5]
Schreiber RD(2015)Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer N Engl J Med 372 2018-2028
[6]
Smyth MJ(2016)Programmed cell death ligand-1 blockade in urothelial bladder cancer: to select or not to select J Clin Oncol 34 3115-3116
[7]
Galon J(2006)The PD-1–PD-L pathway in immunological tolerance Trends Immunol 27 195-201
[8]
Costes A(2000)Engagement of the Pd-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation J Exp Med 192 1027-1034
[9]
Sanchez-Cabo F(2008)PD-1 and its ligands in tolerance and immunity Annu Rev Immunol 26 677-704
[10]
Kirilovsky A(2015)PD-L1 expression as a predictive biomarker in cancer immunotherapy Mol Cancer Ther 14 847-856